[go: up one dir, main page]

CL2016000753A1 - Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+. - Google Patents

Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+.

Info

Publication number
CL2016000753A1
CL2016000753A1 CL2016000753A CL2016000753A CL2016000753A1 CL 2016000753 A1 CL2016000753 A1 CL 2016000753A1 CL 2016000753 A CL2016000753 A CL 2016000753A CL 2016000753 A CL2016000753 A CL 2016000753A CL 2016000753 A1 CL2016000753 A1 CL 2016000753A1
Authority
CL
Chile
Prior art keywords
parkison
dopamine
attenuation
receptor
inhibiting
Prior art date
Application number
CL2016000753A
Other languages
English (en)
Spanish (es)
Inventor
Rodrigo Pacheco
Hugo Gonzalez
Francisco Contreras
Valentina Ugalde
Daniela Elgueta
Original Assignee
Fund Ciencia Para La Vida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Ciencia Para La Vida filed Critical Fund Ciencia Para La Vida
Priority to CL2016000753A priority Critical patent/CL2016000753A1/es
Priority to PCT/IB2017/051868 priority patent/WO2017168390A2/fr
Publication of CL2016000753A1 publication Critical patent/CL2016000753A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/815—Dopamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2016000753A 2016-03-31 2016-03-31 Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+. CL2016000753A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2016000753A CL2016000753A1 (es) 2016-03-31 2016-03-31 Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+.
PCT/IB2017/051868 WO2017168390A2 (fr) 2016-03-31 2017-03-31 Atténuation de la neurodégénérescence associée à la maladie de parkinson par inhibition du récepteur dopaminergique du type d3 dans les lymphocytes t cd4+

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2016000753A CL2016000753A1 (es) 2016-03-31 2016-03-31 Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+.

Publications (1)

Publication Number Publication Date
CL2016000753A1 true CL2016000753A1 (es) 2017-11-10

Family

ID=59963679

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000753A CL2016000753A1 (es) 2016-03-31 2016-03-31 Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+.

Country Status (2)

Country Link
CL (1) CL2016000753A1 (fr)
WO (1) WO2017168390A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016474A1 (fr) * 2019-07-23 2021-01-28 Fundación Ciencia Para La Vida (Fcv) Thérapie ibd par inhibition de drd3 dans des lymphocytes t régulateurs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2343679A (en) * 1998-11-16 2000-05-17 Alison Miriam Davies Autologous transplantation and method for making cells dormant
WO2003037247A2 (fr) * 2001-10-29 2003-05-08 Yeda Research And Development Co. Ltd. Procedes et compositions pharmaceutiques de modulation dopaminergique de l'adherence et de l'activite de cellules t
AU2003267201B2 (en) * 2002-09-14 2009-04-23 The Gov't Of The U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Structurally rigid dopamine D3 receptor selective ligands and process for making them

Also Published As

Publication number Publication date
WO2017168390A3 (fr) 2017-11-16
WO2017168390A2 (fr) 2017-10-05

Similar Documents

Publication Publication Date Title
IL257840A (en) T cell receptors recognizing hla-cw8 restricted mutated kras
PT3149031T (pt) Receptores de células t anti-e7 do papilomavírus humano 16
MA40770A (fr) Dérivés d'imidazoles pentacyclic fusionnés
BR112017024618A2 (pt) agonistas de triazol do receptor apj.
EP3518708A4 (fr) Structure d'assise souple
LT3348317T (lt) Žaislas, paeiliui atskleidžiantis vaikui staigmenas
TWM533465U (en) Improved straw structure
EP3529267C0 (fr) Récepteur de lymphocytes t
FR3048272B1 (fr) Longe d'assurage equipee d'un emerillon perfectionne.
FR3016379B1 (fr) Banche de coffrage avec escalier integre.
CL2016000753A1 (es) Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+.
EP3871657A4 (fr) Composition permettant de renforcer la barrière cutanée
ITUA20163369A1 (it) Guida di estrazione per cassetti o simili dotata di mezzi di regolazione.
FR3035461B1 (fr) Palier a roulement equipe d'un dispositif de blocage
JP2016172986A5 (fr)
NO20160036A1 (en) Tidal powerplant
BR112016028542A2 (pt) implemento de cuidado oral.
PL3148588T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia choroby parkinsona
PT2915426T (pt) Utilização de compostos para a contenção de sintomas de uma doença conhecida nos principais cultivos agrícolas
GB201405907D0 (en) Capturing the angel's share
IT201700058125A1 (it) Struttura di berretto con funzionalita' migliorata.
FR3034635B1 (fr) Siege avec plaque d'assise amovible.
UA34050S (uk) Стрічка полімерна «штучний ротанг»
UA34048S (uk) Стрічка полімерна «штучний ротанг»
UA31376S (uk) Ювелірний виріб «сонце в короні»